| Literature DB >> 32140282 |
Abstract
Nasal polyps are a concern for both adults and children. The treatment of nasal polyps typically is glucocorticoids, both topically and systemically administered. However, patients often experience refractory nasal polyps. A proposed reason for unsatisfactory treatment for the reoccurrence of nasal polyps is because of the drug delivery options through the nose that requires patients to coordinate actuation, head placement, and administration. In addition, many of these delivery systems have shown poor delivery efficiency due to medication depositing into the lungs. To combat these difficulties, Optinose has created an exhalation delivery system that could be used for both liquid and powered medications. Xhance® (fluticasone propionate), which uses this new delivery system, is currently approved for the treatment of nasal polyps in adults. It has shown promising results in adults and is currently undergoing evaluation in pediatric patients. Copyright 2019, Mary Ann Liebert, Inc., publishers.Entities:
Keywords: exhalation delivery system; inflammation; nasal delivery; nasal polyps
Year: 2019 PMID: 32140282 PMCID: PMC7057051 DOI: 10.1089/ped.2019.1066
Source DB: PubMed Journal: Pediatr Allergy Immunol Pulmonol ISSN: 2151-321X Impact factor: 1.349